BHC logo

Bausch Health Companies (BHC) Stock

Profile

Sector:

Healthcare

Country:

Canada

IPO:

29 March 1994

Indexes:

Not included

Description:

Bausch Health Companies is a global healthcare company that develops, manufactures, and markets a range of pharmaceutical products. They focus on eye health, dermatology, and gastrointestinal treatments, aiming to improve patients' lives through innovative therapies and solutions.

Key Details

Price

$7.46

Annual Revenue

$8.76 B(+7.79% YoY)

Annual EPS

-$1.62(-161.29% YoY)

Annual ROE

-665.17%

Beta

0.99

Events Calendar

Earnings

Next earnings date:

Feb 21, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Nov 10, 2010
Splits

Next split:

N/A

Recent split:

Oct 16, 2000

Analyst ratings

Recent major analysts updates

01 Nov '24 RBC Capital
Sector Perform
02 Aug '24 RBC Capital
Sector Perform
02 Aug '24 Piper Sandler
Underweight
25 July '24 Truist Securities
Hold
10 July '24 Raymond James
Market Perform
23 Apr '24 RBC Capital
Sector Perform
12 Apr '24 RBC Capital
Sector Perform
05 Apr '24 RBC Capital
Sector Perform
23 Feb '24 RBC Capital
Sector Perform
20 Sept '23 Jefferies
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Contact lens maker Bausch + Lomb says it is exploring sale
Contact lens maker Bausch + Lomb says it is exploring sale
Contact lens maker Bausch + Lomb says it is exploring sale
BHC
reuters.com12 December 2024

Bausch + Lomb is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health exit the eye-care company.

Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
BHC
seekingalpha.com06 December 2024

Bausch Health Companies Inc.'s debt burden remains a critical issue, with over $21 billion in long-term debt, making a sale of Bausch + Lomb Corporation a potential solution. Bausch + Lomb's Q3 performance showed revenue growth and a shift to net income, driven by new products like Xiidra and Miebo. Despite bankruptcy rumors, major institutional investors like Carl Icahn and Paulson & Co. suggest strategic moves could prevent such an outcome.

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
BHC
accesswire.com05 December 2024

LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids.

Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors
BHC
seekingalpha.com02 December 2024

Bausch Health Companies is undervalued, with a positive outlook for 2024 and solvency reassurance for 2025. The complete spin-off of Bausch + Lomb (B+L) will benefit BHC and is expected to improve its future profitability and financial health. BHC's innovative pipeline and proven track record of innovation will offset revenue loss from the spin-off and support future growth.

Bausch (BHC) Upgraded to Buy: Here's What You Should Know
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
BHC
zacks.com25 November 2024

Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
BHC
reuters.com18 November 2024

The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan.

Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
BHC
zacks.com04 November 2024

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
BHC
zacks.com01 November 2024

BHC's third-quarter adjusted earnings and revenues beat estimates. The increase in revenue guidance is positive.

Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
BHC
accesswire.com08 October 2024

Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure patients receive timely, optimal care1 LAVAL, QC / ACCESSWIRE / October 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today released Liver Health Trends Report in Action, the latest Liver Health Annual Trends Report dedicated to sparking actionable change to improve liver disease management and outcomes for patients. Healthcare provider (HCP) survey participants called for holistic, multi-disciplinary treatment approaches, consistent use of non-invasive screening tools (e.g.

Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
BHC
marketbeat.com25 September 2024

Bausch Health NYSE: BHC stock has been on a wild ride recently, with a dramatic surge in value over the last month. The catalyst for this surge is a wave of rumors suggesting that Bausch + Lomb NYSE: BLCO, Bausch Health's spinoff eye care business, is considering a buyout.

FAQ

  • What is the primary business of Bausch Health Companies?
  • What is the ticker symbol for Bausch Health Companies?
  • Does Bausch Health Companies pay dividends?
  • What sector is Bausch Health Companies in?
  • What industry is Bausch Health Companies in?
  • What country is Bausch Health Companies based in?
  • When did Bausch Health Companies go public?
  • Is Bausch Health Companies in the S&P 500?
  • Is Bausch Health Companies in the NASDAQ 100?
  • Is Bausch Health Companies in the Dow Jones?
  • When was Bausch Health Companies's last earnings report?
  • When does Bausch Health Companies report earnings?
  • Should I buy Bausch Health Companies stock now?

What is the primary business of Bausch Health Companies?

Bausch Health Companies is a global healthcare company that develops, manufactures, and markets a range of pharmaceutical products. They focus on eye health, dermatology, and gastrointestinal treatments, aiming to improve patients' lives through innovative therapies and solutions.

What is the ticker symbol for Bausch Health Companies?

The ticker symbol for Bausch Health Companies is NYSE:BHC

Does Bausch Health Companies pay dividends?

No, Bausch Health Companies does not pay dividends

What sector is Bausch Health Companies in?

Bausch Health Companies is in the Healthcare sector

What industry is Bausch Health Companies in?

Bausch Health Companies is in the Drug Manufacturers - Specialty & Generic industry

What country is Bausch Health Companies based in?

Bausch Health Companies is headquartered in Canada

When did Bausch Health Companies go public?

Bausch Health Companies's initial public offering (IPO) was on 29 March 1994

Is Bausch Health Companies in the S&P 500?

No, Bausch Health Companies is not included in the S&P 500 index

Is Bausch Health Companies in the NASDAQ 100?

No, Bausch Health Companies is not included in the NASDAQ 100 index

Is Bausch Health Companies in the Dow Jones?

No, Bausch Health Companies is not included in the Dow Jones index

When was Bausch Health Companies's last earnings report?

Bausch Health Companies's most recent earnings report was on 30 October 2024

When does Bausch Health Companies report earnings?

The next expected earnings date for Bausch Health Companies is 21 February 2025

Should I buy Bausch Health Companies stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions